<DOC>
	<DOCNO>NCT00020800</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab plus fludarabine treating patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Rituximab Plus Fludarabine Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response time treatment failure patient Waldenstrom 's macroglobulinemia treat rituximab fludarabine . - Determine toxicity regimen patient . - Determine molecular remission achievable patient attain clinical complete response treat regimen . OUTLINE : This multicenter study . Patients receive rituximab IV 3-6 hour weekly week 1-4 , 17 , 18 , 30 , 31 fludarabine IV 10-30 minute daily 5 day week 5 , 9 , 13 , 19 , 23 , 27 . Patients follow least every 2 month 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Waldenstrom 's macroglobulinemia CD20 positive bone marrow immunohistochemistry flow cytometry Presence monoclonal paraprotein IgM level least 2 time upper limit normal ( ULN ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 25,000/mm^3 Hepatic : Bilirubin le 2.5 time ULN SGOT less 2.5 time ULN Renal : Creatinine le 2.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study No serious comorbid disease No uncontrolled bacterial , fungal , viral infection No active malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior rituximab No prior nucleoside analogue therapy Chemotherapy : At least 30 day since prior chemotherapy Endocrine therapy : At least 30 day since prior steroid therapy No concurrent corticosteroid Radiotherapy : At least 30 day since prior radiotherapy Surgery : Not specify Other : No 2 prior course therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>